Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium
ICD-10 F13.931 is a billable code used to indicate a diagnosis of sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium.
F13.931 refers to a condition characterized by the use of sedative, hypnotic, or anxiolytic substances leading to withdrawal delirium. This condition arises when an individual who has developed a dependence on these substances suddenly reduces or stops their intake, resulting in severe psychological and physiological symptoms. Withdrawal delirium can manifest as confusion, agitation, hallucinations, and autonomic instability, which may require immediate medical intervention. The diagnosis is often made based on the patient's history of substance use, clinical presentation, and the exclusion of other potential causes of delirium. Treatment typically involves supportive care, monitoring, and possibly pharmacological interventions to manage symptoms. Understanding the nuances of this diagnosis is crucial for effective treatment and accurate coding, as it reflects the complexities of substance use disorders and the challenges faced by healthcare providers in managing withdrawal symptoms.
Detailed patient history, including substance use patterns and withdrawal symptoms.
Patients presenting with acute confusion and agitation after cessation of sedative use.
Consideration of co-occurring mental health disorders and the need for a comprehensive treatment plan.
Thorough assessment of substance use history and current withdrawal symptoms.
Patients in detoxification programs experiencing withdrawal delirium.
Integration of behavioral therapies and pharmacological management in treatment plans.
Used when managing a patient with withdrawal symptoms in an outpatient setting.
Document the patient's history, examination findings, and treatment plan.
Psychiatric evaluations may require additional documentation of mental status.
Documenting withdrawal symptoms is crucial for accurate coding and treatment planning. It helps differentiate between withdrawal delirium and other conditions, ensuring appropriate care and reimbursement.
